BeOne Medicines (ONC) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BeOne Medicines (ONC) has outperformed Sanofi (SNY) over the past year, gaining 6.6% versus a loss of 18.3%. Over five years, ONC leads with a +1.6% price change compared with -17.7% for SNY. Sanofi is the larger company by market cap ($96.40 billion vs $39.83 billion), about 2.4 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 34.2x for BeOne Medicines). Sanofi pays a dividend yielding 10.24%, while BeOne Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | SNY |
|---|---|---|
| Share price | $350.13 | $40.23 |
| Market cap | $39.83B | $96.40B |
| 1-day change | -3.82% | +0.07% |
| YTD return | +19.82% | -17.04% |
| 1-year return | +6.56% | -18.29% |
| 5-year return | +1.56% | -17.71% |
| P/E ratio (TTM) | 62.64 | 21.17 |
| Forward P/E | 34.15 | 7.45 |
| EPS (TTM) | $5.59 | $1.90 |
| Dividend yield | 0.00% | 10.24% |
| Annual dividend | $0.00 | $4.12 |
| Revenue (latest FY) | $5.34B | — |
| Revenue growth (YoY) | +40.23% | — |
| Net income (latest FY) | $286.93M | — |
| Gross margin | 87.49% | — |
| Operating margin | 8.37% | — |
| Net margin | 5.37% | — |
| 52-week high | $385.22 | $52.68 |
| 52-week low | $253.95 | $39.18 |
| Distance from 52-week high | -9.11% | -23.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.30% | +33.26% |
| Average volume | 388.88K | 2.89M |
| Shares outstanding | 104.92M | 2.40B |
| Employees | 12,000 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sanofi is about 2.4 times larger than BeOne Medicines by market value ($96.40B vs $39.83B).
- ONC has outperformed SNY by 24.8 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (62.6x vs 21.2x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (10.24% vs 0.00%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
ONC vs SNY FAQ
Which is bigger, BeOne Medicines or Sanofi?
Sanofi (SNY) is larger, with a market capitalization of $96.40B compared with $39.83B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ONC or SNY?
ONC returned +6.56% over the past 12 months, compared with -18.29% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ONC or SNY?
SNY has the lower trailing P/E at 21.2, versus 62.6 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BeOne Medicines or Sanofi?
Sanofi pays a dividend yielding 10.24%, while BeOne Medicines does not currently pay a regular dividend.
Are BeOne Medicines and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.